What is the current market size and future outlook for the breath biopsy testing market?
The breath biopsy testing market size has grown strongly in recent years. It will grow from $3.18 $ billion in 2024 to $3.43 $ billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to supportive government programs, shift toward non-invasive diagnostics, rising consumer awareness of preventive healthcare, increasing use in oncology research, growing application in metabolic disorders.
The breath biopsy testing market size is expected to see strong growth in the next few years. It will grow to $4.57 $ billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to rising incidence of respiratory diseases, growing awareness of early disease detection, expansion of clinical research and trials, rising geriatric population, growing prevalence of infectious diseases. Major trends in the forecast period include technological advancements in breath analysis, demand for personalized medicine, investments in healthcare infrastructure, collaborations between diagnostic companies and hospitals, adoption of ai and data analytics.
Get Your Free Sample of The Global Breath Biopsy Testing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19351&type=smp
How has the breath biopsy testing market evolved, and what factors have shaped its growth?
The rising prevalence of respiratory diseases is expected to propel the growth of the breath biopsy testing market going forward. Respiratory diseases refer to medical conditions that impact on the lungs and airways, hindering a person’s ability to breathe efficiently. The prevalence of respiratory diseases is due to increasing environmental pollution, higher rates of smoking, and the growing prevalence of chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD). Breath biopsy testing is required for respiratory diseases to offer a non-invasive, rapid, and potentially more accurate method for detecting biomarkers associated with these conditions, improving early diagnosis and management. For instance, in November 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based government agency, the United States reported around 8,331 tuberculosis cases in 2022, reflecting a 5.9% increase from 2021. The incidence rate rose to 2.5 cases per 100,000 people, marking a 5.5% increase compared to the previous year. Therefore, the rising prevalence of respiratory diseases will drive the growth of the breath biopsy testing market.
What are the major segments of the breath biopsy testing market?
The breath biopsy testingmarket covered in this report is segmented –
1) By Type: Volatile Organic Compound Analyzers, Breath Biopsy Kits, Breath Sampler, Other Types
2) By Technology: Fuel Cell Technology, Semiconductor Sensor, Infrared (IR) Spectroscopy, Other Technologies
3) By Application: Hospitals, Clinics, Diagnostics Laboratories, Other Applications
Subsegments:
1) By Volatile Organic Compound (VOC) Analyzers: Gas Chromatography-Mass Spectrometry (GC-MS) Analyzers, Photoionization Detectors (PID), Electronic Nose Devices
2) By Breath Biopsy Kits: Sample Collection Kits, Analysis Kits For Specific Biomarkers, Packaging And Transport Kits
3) By Breath Sampler: Breath Collection Bags, Breath Sampling Tubes, Portable Breath Sampling Devices
4) By Other Types: Breath Testing Devices For Specific Conditions, Software For Data Analysis, Calibration Devices For Breath Analyzers
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/breath-biopsy-testing-global-market-report
Which companies dominate the breath biopsy testing market?
Major companies operating in the breath biopsy testing market are Drägerwerk AG & Co. KGaA, Intoximeters Inc., Owlstone Medical Ltd., SKC Inc., Lifeloc Technologies Inc., Alcolizer Pty Ltd., Breathomix, Aerocrine AB, Bedfont Scientific Ltd., AK GlobalTech Corp., Alveo Technologies Inc., Andatech Pty Ltd., BACtrack, Biosensia Ltd., Ionicon, Ketonix AB, Lion Laboratories Limited, Menssana Research Inc., Microplex Inc., Quest Products Inc., Rapid Biosensor Systems Ltd., RoboScientific Ltd., Spirosure
How will evolving trends contribute to the growth of the breath biopsy testing market?
Major companies operating in the breath biopsy testing market are focused on developing innovative products, such as breath analyzers, to detect asthma. Breath analyzers are diagnostic devices that detect and measure specific compounds in a person’s breath to identify medical conditions or assess health status. For instance, in May 2023, GenWorks, an India-based healthcare solutions provider, launched the FenomPro breath analyzer. The FenomPro breath analyzer offers a unique feature with its rapid FeNO testing capability, delivering results in just 28 seconds. Designed for ease of use in clinical settings, it provides accurate assessments for diagnosing, screening, and monitoring asthma. The device is equipped with a rechargeable battery for portability, features a user-friendly interface, and efficiently determines whether patients need treatment or inhaler prescriptions.
What are the key regional dynamics of the breath biopsy testing market, and which region leads in market share?
North America was the largest region in the breath biopsy testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breath biopsy testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Breath Biopsy Testing Market Report 2025 Offer?
The breath biopsy testing market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Breath biopsy testing is a non-invasive diagnostic method that analyzes the chemical compounds in a person’s breath to detect and diagnose diseases. This testing is based on the principle that certain diseases, metabolic conditions, and physiological states produce unique chemical markers or volatile organic compounds (VOCs) that can be detected in the exhaled breath.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19351
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
